Learn About Pancreatic Ductal Adenocarcinoma
The Medical College Of Wisconsin Inc
Ben George is a Hematologist Oncology specialist and a Hematologist in Milwaukee, Wisconsin. Dr. George and is rated as an Elite provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Pancreatectomy, and Gallbladder Removal. Dr. George is currently accepting new patients.
Daniel Renouf practices in Vancouver, Canada. Mr. Renouf and is rated as an Elite expert by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. His top areas of expertise are Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Familial Pancreatic Cancer, and Colorectal Cancer.
The University Of Texas Health Science Center At San Antonio
Lei Zheng is an Oncologist in San Antonio, Texas. Dr. Zheng and is rated as an Elite provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery. Dr. Zheng is currently accepting new patients.
Summary: The purpose of this study is to evaluate the safety and clinical activity of maintenance olaparib and pembrolizumab following multi-agent, low dose chemotherapy with gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in patients with untreated metastatic pancreatic ductal cancer.
Summary: The main purpose of this research study is to determine the maximum tolerable dose (MTD) of SX-682 in combination with nivolumab in patients with metastatic pancreatic ductal adenocarcinoma who have completed at least 16 weeks of first line chemotherapy treatment without evidence of disease progression.